EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Seasonal variation in immune-related adverse events in advanced cancer patients

Roger Liang, Bo Gao, Adnan Nagrial, Tania Moujaber, Matteo S Carlino, Pei N Ding, Howard Gurney, Mark Wong, Rosemary Habib, Serigne N Lo, Janet McKeown, Ines Pires da Silva

Cancer Immunology, Immunotherapy · 12.05.2026 · 75 (7)

DOI: 10.1007/s00262-026-04423-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 12.05.2026. Verfasst von Roger Liang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia. rlia8791@uni.sydney.edu.au. Hauptthemen laut MEDLINE: Seasons, Neoplasms, Immune Checkpoint Inhibitors, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Sydney.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) improve outcomes across advanced cancers but can cause immune-related adverse events (irAEs). Seasonal environmental factors influence immune regulation and autoimmunity, yet its relationship with irAE development in non-melanoma cancers remains poorly defined.

Methods

We retrospectively analysed patients with advanced non-melanoma solid tumours treated with anti-PD-1/PD-L1 and/or anti-CTLA-4 monotherapy at two Australian tertiary centers between 2014–2024. Seasonal variation in irAE incidence, organ distribution, severity, and timing were evaluated using descriptive analyses, Kaplan–Meier estimates and Cox proportional hazards models.

Results

Among 709 patients across 27 cancer types (median follow-up 12.7 months), 514 irAEs occurred, including 32% grade ≥ 3 events and 14% treatment discontinuation rate due to toxicity. Winter ICI initiation led to the highest irAE rate (0.89 events per treatment) versus summer (0.62), largely driven by seasonal variation in low-grade cutaneous and thyroid events. Summer ICI initiation showed the highest proportion of grade ≥ 3 irAEs, whereas winter had the lowest. Seasonal effects also differed by regimen intensity, with disproportionately more irAEs among patients commencing doublet ICIs in winter. Season of ICI initiation was not significantly associated with overall irAE risk (p = 0.174) or time to onset (p = 0.11). However, time to first irAE differed by season of toxicity onset (p = 0.019), with earlier irAEs occurring in spring and summer.

Conclusions

Although there was no significant association between season of ICI initiation and overall irAE risk, we observed seasonal variations in the phenotype, severity, and timing of irAEs. These exploratory findings may inform future investigation into seasonal influences on immune toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SeasonsNeoplasmsImmune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedAustraliaAdult

Stichwörter der Autor:innen

Advanced cancerImmune checkpoint inhibitorsImmune-related adverse eventsImmunotherapySeasonalToxicity

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia. rlia8791@uni.sydney.edu.au.
  • Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia. rlia8791@uni.sydney.edu.au.
  • Blacktown Cancer & Haematology Centre, Blacktown Hospital, Sydney, NSW, Australia. rlia8791@uni.sydney.edu.au.
  • Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia.
  • Blacktown Cancer & Haematology Centre, Blacktown Hospital, Sydney, NSW, Australia.
  • Westmead Clinical School, The University of Sydney, Sydney, NSW, Australia.

Förderung

  • The University of Sydney

Zitieren

APA

Liang, R., Gao, B., Nagrial, A., Moujaber, T., Carlino, M. S., Ding, P. N., Gurney, H., Wong, M., Habib, R., Lo, S. N., McKeown, J., & da Silva, I. P. (2026). Seasonal variation in immune-related adverse events in advanced cancer patients. Cancer Immunology, Immunotherapy, 75(7). https://doi.org/10.1007/s00262-026-04423-x

Vancouver

Liang R, Gao B, Nagrial A, Moujaber T, Carlino MS, Ding PN, et al. Seasonal variation in immune-related adverse events in advanced cancer patients. Cancer Immunology, Immunotherapy. 2026;75(7). doi:10.1007/s00262-026-04423-x

BibTeX
@article{Liang2026,
  author = {Liang, Roger and Gao, Bo and Nagrial, Adnan and Moujaber, Tania and Carlino, Matteo S and Ding, Pei N and Gurney, Howard and Wong, Mark and Habib, Rosemary and Lo, Serigne N and McKeown, Janet and da Silva, Ines Pires},
  title = {Seasonal variation in immune-related adverse events in advanced cancer patients},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {7},
  doi = {10.1007/s00262-026-04423-x}
}
Kostenlos starten →